Resource allocation decision-making in dementia in Ireland is often characterised as being narrow, implicit and provider-driven, with little knowledge about how priorities are set and addressed, and to what effect. The absence of people with dementia from the decision-making process does much to undermine personhood and citizenship within dementia in Ireland.
Research
DRNI Members Research is a list of ongoing and completed research carried out by DRNI members.
You can search via project type, disease, or Principal Investigator/Researcher name.
Search
Research type
Disease area
Project Aim(s): To explore the perspectives of multiple stakeholders on respite services for dementia, with a view to informing service development in the Irish context.
Project Aim(s): TUDCA-ALS will focus on amyotrophic lateral sclerosis (ALS) a rare neurodegenerative disorder. TUDCA-ALS is based on the results of a successful proof-of-concept trial and has the ambition to develop a novel therapy in patients with ALS, based on administration of tauroursodeoxycholic acid (TUDCA) in addition to riluzole. TUDCA-ALS aims to perform a state-of-art randomized control trial on safety and efficacy of TUDCA in patients with sporadic ALS, without cognitive involvement and to exploit the project results into a novel therapeutic treatment for ALS.
Sampling and biomarker OPtimization and Harmonization In ALS and other motor neuron disease (SOPHIA)
SOPHIA is a consortium of 17 ALS centres in Europe. The consortium aim to develop a common strategy for the prioritization and harmonization of biomarkers for ALS and neurodegenerative diseases. In particular, it aims to validate neurochemical biomarkers for monitoring disease activity, for generating earlier diagnoses and for defining prognosis.
Sampling and biomarker OPtimization and Harmonization In ALS and other motor neuron disease (SOPHIA)
SOPHIA is a consortium of 17 ALS centres in Europe. The consortium aim to develop a common strategy for the prioritization and harmonization of biomarkers for ALS and neurodegenerative diseases. In particular, it aims to validate neurochemical biomarkers for monitoring disease activity, for generating earlier diagnoses and for defining prognosis.
Project Aim(s): Development of optimally informative biomarkers for ALS, and establishment of stakeholder agreement regarding their use. This will be achieved by defining, validating and harmonizing optimal methodologies that can be reliably implemented within a pan-European framework program.
Project Aim(s): To test a software engine for the prevention of adverse drug reactions in multimorbid older patients hospitalized with acute illness.
Project Aim(s): The development of neurotrophic factor therapy for Parkinson's disease (PD).
We are a PhD training programme, linking together approximately 90 genomics data science group leaders based at five Irish institutions. Expertise within the group spans from statistical modeling and machine learning to the full range of application of genomics. Over the coming four years our research teams will be joined by 100 fully funded PhD students, recruited through this Centre.
Project Aim(s): To examine how Ataxin-2 and Stress_Granule Modulatory Proteins function in ALS/FTD.